Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment [Phase 3]

View source ↗

Summary

Phase 3 study assessing ibrexafungerp in patients with invasive and mucocutaneous fungal diseases refractory to or intolerant of standard treatment has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blastomycosis
• Coccidioidomycosis
• Histoplasmosis
• Invasive Candidiasis
• Invasive Pulmonary Aspergillosis
• Mucocutaneous Candidiasis
• Pulmonary Aspergillosis
• Vulvovaginal Candidiasis

Drugs mentioned

• Ibrexafungerp (ibrexafungerp)

Snippet

Sponsor: Scynexis, Inc. | Conditions: Invasive Candidiasis, Mucocutaneous Candidiasis | Phase 3 | Status: COMPLETED | Results posted: 2024-11-20